MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fonc.2026.1865921

Медицинская библиотека · Frontiers in oncology · 2026

Prolonged survival in a HER2 positive metastatic breast cancer patient with brain metastases treated with TDM1 after failure of next generation HER2 targeted therapies: case report.

Trevisan Benedetta, Cosentini Deborah, Schivardi Greta, Piazza Francesca, Scartabellati Giulia, Moretti Laura, Vassalli Lucia, Ippolito Giuseppe, Donato Francesco, Berruti Alfredo, Laganà Marta, Pedersini Rebecca

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Brain metastases (BM) occur in up to 50% of patients with HER2-positive metastatic breast cancer (MBC) and represent a major clinical challenge due to limited CNS drug penetration. In recent years, novel anti-HER2 agents-such as trastuzumab deruxtecan (T-DXd) and tucatinib-have shown promising intracranial efficacy and are now recommended after progression on first-line therapies. However, no prospective data are available to guide optimal treatment sequencing, particularly in the CNS setting.

CASE PRESENTATION: We report the case of a 37-year-old woman with HER2-positive, hormone receptor-negative MBC and symptomatic BM who progressed after treatment with T-DXd and a tucatinib-based regimen. Remarkably, fourth-line therapy with Trastuzumab Emtansine (T-DM1) resulted in a durable intracranial response, maintained over 24 months, with good clinical tolerance and manageable side effects.

RESULTS

this case underscores the potential of T-DM1 to remain an effective treatment option even after the failure of next-generation HER2-targeted therapies. The sustained response may be attributed to tumor biology, prior radiotherapy-induced modulation of the blood-brain barrier, or enhanced drug delivery to CNS lesions. Given its favorable toxicity profile and ease of administration, T-DM1 retains clinical relevance in selected patients.

CONCLUSION

T-DM1 may offer meaningful benefit in HER2+ MBC with BM, especially where newer agents fail or are contraindicated. Further studies are needed to clarify optimal sequencing strategies.

Для цитирования: Trevisan Benedetta, Cosentini Deborah, Schivardi Greta, Piazza Francesca, Scartabellati Giulia, Moretti Laura, Vassalli Lucia, Ippolito Giuseppe, Donato Francesco, Berruti Alfredo, Laganà Marta, Pedersini Rebecca. Prolonged survival in a HER2 positive metastatic breast cancer patient with brain metastases treated with TDM1 after failure of next generation HER2 targeted therapies: case report.. Frontiers in oncology. 2026. DOI: 10.3389/fonc.2026.1865921.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.